Cancer

Study Shows ctDNA Test Detects Immunotherapy Response Early

A new study found the assay detected immunotherapy response in advanced cancer patients a median of 23 days after treatment—over five months earlier than imaging.

Cancer

Labcorp Expands MRD Testing Portfolio for Three Cancer Types

Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.

Cancer

Why Cervical Cancer Screening Rates Are Falling—and What Could Help Reverse the Trend

Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.

Studies Find Merlin CP-GEP Test Improved Melanoma Risk Stratification

Dec 18, 2025 | Melanoma

Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.

Roche Gains FDA Approval for Expanded HER2 Diagnostic Test Indications

Dec 15, 2025 | Breast

The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.

Test Validated to Predict Recurrence Risk and Radiation Therapy Benefit in Breast Cancer

Dec 12, 2025 | Breast

A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.

Cell-Free DNA Test May Identify Immunotherapy Adverse Events Earlier

Dec 12, 2025 | Cancer

Johns Hopkins researchers found the blood test detected multiorgan tissue damage in patients experiencing immune-related adverse events from checkpoint inhibitor therapy.

Ultrasensitive ctDNA Test Shows Promise for Lung Cancer Monitoring

Dec 11, 2025 | Lung Cancer

A study of 431 patients demonstrates the test can detect cancer recurrence months ahead of standard imaging.

Study Identifies Factors That Interfere with Cancer Detection in Liquid Biopsy

Dec 9, 2025 | Cancer

Research analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.

Natera Acquires Foresight Diagnostics in $450 Million Deal

Dec 8, 2025 | Lymphoma

Transaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.

New Partnership Aims to Expand Access to AI-Driven Cancer Genomic Testing

Dec 5, 2025 | Analytical Software Systems, Cancer, Molecular Diagnostics

The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.